Novel treatments for anxiety and depression: hurdles in bringing them to the market
- 20 November 2001
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 6 (23) , 1220-1230
- https://doi.org/10.1016/s1359-6446(01)02043-8
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- The Quality of Care for Depressive and Anxiety Disorders in the United StatesArchives of General Psychiatry, 2001
- Anxiety Disorders in the USA, 1990 to 1997Clinical Drug Investigation, 2000
- Antidepressants: past, present and futureEuropean Journal of Pharmacology, 2000
- SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depressionThe Lancet, 2000
- International Study of Expert Judgment on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: IV. Therapeutic Dose Dependence and Abuse Liability of Benzodiazepines in the Long-Term Treatment of Anxiety DisordersJournal of Clinical Psychopharmacology, 1999
- International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997Depression and Anxiety, 1999
- The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depressionPublished by American Medical Association (AMA) ,1997
- Depression in the communityInternational Clinical Psychopharmacology, 1997
- Recovery from depression: risk or reality?Acta Psychiatrica Scandinavica, 1996
- International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disordersJournal of Affective Disorders, 1995